Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Midazolam for Care Delivery in Elderly Patients With Neurocognitive Disorders
NCT06638710Phase 2Recruiting
- Sponsor
- CHU Grenoble Alpes
- Start
- Jul 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in neurocognitive disorders (NCDs) comparing Placebo with Oral Midazolam (2 arms). Primary endpoint: Evolution of resistance to care following oral administration of midazolam. Started Jul 2025; status: recruiting.
02
Drugs
midazolam
03
Conditions
neurocognitive disorders (NCDs)
Beyond the preview
Go deeper on NCT06638710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06638710.